By Fineline Cube Beijing-based MegaRobo Technologies, a company applying robotics and artificial intelligence (AI) in the life sciences field, has reportedly secured USD 300 million in a Series C financing round. The funding was led by Goldman Sachs, GGV Capital, and Asia Investment Capital, with participation from Sinovation Ventures, Pavilion Capital, Starr Capital, Yumeng Capital, Redview Capital, Harvest Capital, and Taihe Capital. The proceeds will be used to accelerate research and development, expand production capacity, and drive business growth both domestically and internationally.
Company Background and Technology
Founded in 2016, MegaRobo Technologies offers a comprehensive suite of robotic automation solutions integrating AI software, analytical instruments, laboratory hardware, and consumables. The company has established an intelligent automatic biological laboratory and has made significant strides in niche markets such as organoid research, cell and gene therapy, gene editing, chemical synthesis, and nerve regeneration.
Future Outlook
With the fresh capital, MegaRobo aims to further enhance its technological edge in the life sciences sector. The company’s innovative approach to laboratory automation and AI-driven solutions positions it well to meet growing demand for efficiency and precision in research and development.-Fineline Info & Tech